Based on our Pharmacor Prostate Cancer advisory service, Decision Resources is offering an exclusive analyst call entitled How Will Johnson & Johnson’s Zytiga Compete in the Increasingly Competitive Prostate Cancer Drug Market?

Recorded live on Tuesday, May 17, 2011

This 15-minute analyst call, presented by Decision Resources Analyst Rachel Webster, M.Sc. D.Phil., will answer the following questions:

• What are the advantages of Zytiga over currently available agents used to treat MCRPC?
• What clinical evidence supports the use of Zytiga over current standards of care?
• How will Zytiga compete in the current treatment paradigm and how will it fair against other emerging agents that Decision Resources’ forecasts to launch for prostate cancer?
• What is Decision Resources’ sales forecast through 2019 for Zytiga in the world’s major pharmaceutical markets?

This analyst call was held on May 17, 2011. Contact us to learn how you can purchase this service and access the recording.

Click here to view the invite.